The effects of vitamin B on the immune/cytokine network and their involvement in depression

Maturitas

Volumn 96, Issue , 2017, Pages 58-71

  Mikkelsen, Kathleen ^a   Stojanovska, Lily ^a   Prakash, Monica ^a   Apostolopoulos, Vasso ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Depression; Immune cells; Immune system; Inflammation; Mental health

Indexed keywords

BIOTIN; CYANOCOBALAMIN; CYTOKINE; FOLIC ACID; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; NICOTINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TUMOR NECROSIS FACTOR; VITAMIN B COMPLEX; VITAMIN B GROUP;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DEPRESSION; DRUG EFFECT; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; META ANALYSIS (TOPIC); MONOCYTE; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; RIBOFLAVIN DEFICIENCY; SYSTEMATIC REVIEW; T FOLLICULAR HELPER CELL; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; THIAMINE DEFICIENCY; VAGUS NERVE STIMULATION; COMPLICATION; IMMUNOLOGY; VITAMIN DEFICIENCY;

CYTOKINES; DEPRESSION; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-1; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN B COMPLEX; VITAMIN B DEFICIENCY;

EID: 85000501138     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.11.012     Document Type: Review

References (146)

1. [1] Schaible, U.E., Kaufmann, S.H., Malnutrition and infection: complex mechanisms and global impacts. PLoS Med., 4, 2007, e115.
2. [2] Bull, S.J., Huezo-Diaz, P., Binder, E.B., Cubells, J.F., Ranjith, G., Maddock, C., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 14 (2009), 1095–1104.
3. [3] Cunningham-Rundles, S., McNeeley, D.F., Moon, A., Mechanisms of nutrient modulation of the immune response. J. Allergy Clin. Immunol. 115 (2005), 1119–1128 quiz 29.
4. [4] Pavlov, V.A., Tracey, K.J., The vagus nerve and the inflammatory reflex—linking immunity and metabolism. Nat. Rev. Endocrinol. 8 (2012), 743–754.
5. [5] Walker, E.R., McGee, R.E., Druss, B.G., Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72 (2015), 334–341.
6. [6] Jabbar, A., Yawar, A., Waseem, S., Islam, N., Ul Haque, N., Zuberi, L., et al. Vitamin B12 deficiency common in primary hypothyroidism. JPMA J. Pak. Med. Assoc. 58 (2008), 258–261.
7. [7] BeggS, V.T., Baker, B., Welfare AIoha, (eds.) The Burden of Disease and Injury in Australia, 2003, Autralian Government, ACT.
8. [8] Hickie, I.B., Reducing the burden of depression: are we making progress in Australia?. Med. J. Austr. 181 (2004), S4–S5.
9. [9] Beyondblue, Beyond Blue- Depression and Anxiety. 2014 ( http://wwwbeyondblueorgau).
10. [10] Burns, J., Birrell, E., Enhancing early engagement with mental health services by young people. Psychol. Res. Behav. Manage. 7 (2014), 303–312.
11. [11] van Loo, H.M., de Jonge, P., Romeijn, J.W., Kessler, R.C., Schoevers, R.A., Data-driven subtypes of major depressive disorder: a systematic review. BMC Med., 10, 2012, 156.
12. [12] Shively, C.A., Silverstein-Metzler, M., Justice, J., Willard, S.L., The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy. Neurosci. Biobehav. Rev. 16 (2016), 30111–30117.
13. [13] Park, S.J., Roh, S., Hwang, J., Kim, H.A., Kim, S., Lee, T.K., et al. Association between depression and metabolic syndrome in korean women: results from the korean national health and nutrition examination survey (2007–2013). J. Affect. Disord. 205 (2016), 393–399.
14. [14] Vogiatzoglou, A., Refsum, H., Johnston, C., Smith, S.M., Bradley, K.M., de Jager, C., et al. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology 71 (2008), 826–832.
15. [15] Mikkelsen, K., Stojanovska, L., Apostolopoulos, V., The effects of vitamin B in depression. Curr. Med. Chem., 2016 Sep 20. [Epub ahead of print] PMID: 27655070.
16. [16] Mikkelsen, K., Stojanovska, L., Tangalakis, K., Bosevski, M., Apostolopoulos, V., Cognitive decline: a vitamin B perspective. Maturitas 93 (2016), 108–113.
17. [17] Friedmann, N., Rusou, D., Critical period for first language: the crucial role of language input during the first year of life. Curr. Opin. Neurobiol. 35 (2015), 27–34.
18. [18] Zhang, G., Ding, H., Chen, H., Ye, X., Li, H., Lin, X., et al. Thiamine nutritional status and depressive symptoms are inversely associated among older Chinese adults. J. Nutr. 143 (2013), 53–58.
19. [19] Smidt, L.J., Cremin, F.M., Grivetti, L.E., Clifford, A.J., Influence of thiamin supplementation on the health and general well-being of an elderly Irish population with marginal thiamin deficiency. J. Gerontol. 46 (1991), M16–M22.
20. [20] Bell, I.R., Edman, J.S., Morrow, F.D., Marby, D.W., Perrone, G., Kayne, H.L., et al. Brief communication Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J. Am. Coll. Nutr. 11 (1992), 159–163.
21. [21] Ghaleiha, A., Davari, H., Jahangard, L., Haghighi, M., Ahmadpanah, M., Seifrabie, M.A., et al. Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial. Eur. Arch. Psychiatry Clin. Neurosci. 266 (2016), 695–702.
22. [22] ter Borg, S., Verlaan, S., Hemsworth, J., Mijnarends, D.M., Schols, J.M., Luiking, Y.C., et al. Micronutrient intakes and potential inadequacies of community-dwelling older adults: a systematic review. Br. J. Nutr. 113 (2015), 1195–1206.
23. [23] Pinto, J.T., Cooper, A.J., From cholesterogenesis to steroidogenesis: role of riboflavin and flavoenzymes in the biosynthesis of vitamin D. Adv. Nutr. 5 (2014), 144–163.
24. [24] Thompson, L.J., Proctor, R.C., Depressive and anxiety reactions treated with nicotinic acid and phenobarbital. N. C. Med. J. 14 (1953), 420–426.
25. [25] Prakash, R., Gandotra, S., Singh, L.K., Das, B., Lakra, A., Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy. Gen. Hosp. Psychiatry 30 (2008), 581–584.
26. [26] Smesny, S., Baur, K., Rudolph, N., Nenadic, I., Sauer, H., Alterations of niacin skin sensitivity in recurrent unipolar depressive disorder. J. Affect. Disord. 124 (2010), 335–340.
27. [27] Rubio-Lopez, N., Morales-Suarez-Varela, M., Pico, Y., Livianos-Aldana, L., Llopis-Gonzalez, A., Nutrient intake and depression symptoms in spanish children: the ANIVA study. Int. J. Environ. Res. Public Health, 2016, 13.
28. [28] Davison, K.M., Kaplan, B.J., Nutrient intakes are correlated with overall psychiatric functioning in adults with mood disorders. Can. J. Psychiatry 57 (2012), 85–92.
29. [29] Hvas, A.M., Juul, S., Bech, P., Nexo, E., Vitamin B6 level is associated with symptoms of depression. Psychother. Psychosom. 73 (2004), 340–343.
30. [30] Malouf, R., Grimley Evans, J., The effect of vitamin B6 on cognition. Cochrane Database Syst. Rev., 2003, CD004393.
31. [31] Shiloh, R., Weizman, A., Weizer, N., Dorfman-Etrog, P., Munitz, H., Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression—preliminary open-label trial. Harefuah 140 (2001), 369–373 456.
32. [32] Holsboen, F., Benkert, O., Meier, L., Kreuz-Kersting, A., Combined estradiol and vitamin B6 treatment in women with major depression. Am. J. Psychiatry, 142, 1985, 658.
33. [33] Levenson, J.L., Biotin-responsive depression during hyperalimentation. JPEN J. Parenter. Enteral Nutr. 7 (1983), 181–183.
34. [34] Kiykim, E., Kiykim, A., Cansever, M.S., Zeybek, C.A., Biotinidase deficiency mimicking primary immune deficiencies. BMJ Case Reports, 2015, 2015.
35. [35] Gilbody, S., Lightfoot, T., Sheldon, T., Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J. Epidemiol. Community Health 61 (2007), 631–637.
36. [36] Coppen, A., Bolander-Gouaille, C., Treatment of depression: time to consider folic acid and vitamin B12. J. Psychopharmacol. (Oxf.) 19 (2005), 59–65.
37. [37] Miyake, Y., Sasaki, S., Tanaka, K., Yokoyama, T., Ohya, Y., Fukushima, W., et al. Dietary folate and vitamins B12, B6, and B2 intake and the risk of postpartum depression in Japan: the Osaka Maternal and Child Health Study. J. Affect. Disord. 96 (2006), 133–138.
38. [38] Tolmunen, T., Voutilainen, S., Hintikka, J., Rissanen, T., Tanskanen, A., Viinamaki, H., et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J. Nutr. 133 (2003), 3233–3236.
39. [39] Seppala, J., Koponen, H., Kautiainen, H., Eriksson, J.G., Kampman, O., Leiviska, J., et al. Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study. BMC Psychiatry, 13, 2013, 145.
40. [40] Syed, E.U., Wasay, M., Awan, S., Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial. Open Neurol. J. 7 (2013), 44–48.
41. [41] Walker, J.G., Batterham, P.J., Mackinnon, A.J., Jorm, A.F., Hickie, I., Fenech, M., et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms—the Beyond Ageing Project: a randomized controlled trial. Am. J. Clin. Nutr. 95 (2012), 194–203.
42. [42] Nikkheslat, N., Zunszain, P.A., Horowitz, M.A., Barbosa, I.G., Parker, J.A., Myint, A.M., et al. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav. Immun. 48 (2015), 8–18.
43. [43] Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71 (2014), 1121–1128.
44. [44] Forsythe, P., Bienenstock, J., Kunze, W.A., Vagal pathways for microbiome-brain-gut axis communication. Adv. Exp. Med. Biol. 817 (2014), 115–133.
45. [45] Kelly, J.R., Kennedy, P.J., Cryan, J.F., Dinan, T.G., Clarke, G., Hyland, N.P., Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci., 9, 2015, 392.
46. [46] Rao, A.V., Bested, A.C., Beaulne, T.M., Katzman, M.A., Iorio, C., Berardi, J.M., et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog., 1, 2009, 6.
47. [47] Roman, A., Kreiner, G., Nalepa, I., Macrophages and depression – a misalliance or well-arranged marriage?. Pharmacol. Rep. 65 (2013), 1663–1672.
48. [48] Smith, R.S., The macrophage theory of depression. Med. Hypotheses 35 (1991), 298–306.
49. [49] Miller, A.H., Depression and immunity: a role for T cells?. Brain Behav. Immun. 24 (2010), 1–8.
50. [50] Mazur-Bialy, A.I., Buchala, B., Plytycz, B., Riboflavin deprivation inhibits macrophage viability and activity – a study on the RAW 264.7 cell line. Br. J. Nutr. 110 (2013), 509–514.
51. [51] Zhou, T., Wang, S., Ren, H., Qi, X.R., Luchetti, S., Kamphuis, W., et al. Dendritic cell nuclear protein-1, a novel depression-related protein, upregulates corticotropin-releasing hormone expression. Brain 133 (2010), 3069–3079.
52. [52] Risbrough, V.B., Stein, M.B., Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav. 50 (2006), 550–561.
53. [53] Schatzberg, A.F., Keller, J., Tennakoon, L., Lembke, A., Williams, G., Kraemer, F.B., et al. HPA axis genetic variation, cortisol and psychosis in major depression. Mol. Psychiatry 19 (2014), 220–227.
54. [54] Luckheeram, R.V., Zhou, R., Verma, A.D., Xia, B., CD4(+)T cells: differentiation and functions. Clin. Dev. Immunol., 2012, 2012, 925135.
55. [55] Zhu, J., Yamane, H., Paul, W.E., Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28 (2010), 445–489.
56. [56] Fazilleau, N., Mark, L., McHeyzer-Williams, L.J., McHeyzer-Williams, M.G., Follicular helper T cells: lineage and location. Immunity 30 (2009), 324–335.
57. [57] Linterman, M.A., Beaton, L., Yu, D., Ramiscal, R.R., Srivastava, M., Hogan, J.J., et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207 (2010), 353–363.
58. [58] Spolski, R., Leonard, W.J., IL-21 and T follicular helper cells. Int. Immunol. 22 (2010), 7–12.
59. [59] Romagnani, S., Th1/Th2 cells. Inflamm. Bowel Dis. 5 (1999), 285–294.
60. [60] Myint, A.M., Leonard, B.E., Steinbusch, H.W., Kim, Y.K., Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 88 (2005), 167–173.
61. [61] Martino, M., Rocchi, G., Escelsior, A., Fornaro, M., Immunomodulation mechanism of antidepressants: interactions between Serotonin/Norepinephrine balance and Th1/Th2 balance. Curr. Neuropharmacol. 10 (2012), 97–123.
62. [62] Mohr, D.C., Goodkin, D.E., Islar, J., Hauser, S.L., Genain, C.P., Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. 58 (2001), 1081–1086.
63. [63] Kim, Y.K., Suh, I.B., Kim, H., Han, C.S., Lim, C.S., Choi, S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 7 (2002), 1107–1114.
64. [64] Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34 (1995), 301–309.
65. [65] Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., Kirchner, H., Increased CD56+ natural killer cells and related cytokines in major depression. Clin. Immunol. Immunopathol. 78 (1996), 83–85.
66. [66] Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O., et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin. Dev. Immunol., 2007, 2007, 76396.
67. [67] Song, C., Halbreich, U., Han, C., Leonard, B.E., Luo, H., Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42 (2009), 182–188.
68. [68] Kaplan, M.H., Th9 cells: differentiation and disease. Immunol. Rev. 252 (2013), 104–115.
69. [69] Davami, M.H., Baharlou, R., Ahmadi Vasmehjani, A., Ghanizadeh, A., Keshtkar, M., Dezhkam, I., et al. Elevated IL-17 and TGF-beta serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic Clin. Neurosci. 7 (2016), 137–142.
70. [70] Li, Y., Xiao, B., Qiu, W., Yang, L., Hu, B., Tian, X., et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. J. Affect. Disord. 124 (2010), 68–75.
71. [71] Kunisawa, J., Hashimoto, E., Ishikawa, I., Kiyono, H., A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. PLoS One, 7, 2012, e32094.
72. [72] Grosse, L., Carvalho, L.A., Birkenhager, T.K., Hoogendijk, W.J., Kushner, S.A., Drexhage, H.A., et al. Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology (Berl.) 233 (2015), 1679–1688.
73. [73] Kubota, K., Kurabayashi, H., Kawada, E., Okamoto, K., Shirakura, T., Restoration of abnormally high CD4/CD8 ratio and low natural killer cell activity by vitamin B12 therapy in a patient with post-gastrectomy megaloblastic anemia. Intern. Med. 31 (1992), 125–126.
74. [74] Leitenberger, J.J., Berthelot, C.N., Polder, K.D., Pro, B., McLaughlin, P., Jones, D., et al. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J. Am. Acad. Dermatol. 58 (2008), 480–484.
75. [75] Partearroyo, T., Ubeda, N., Montero, A., Achon, M., Varela-Moreiras, G., Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats. Nutrients 5 (2013), 4836–4848.
76. [76] Tamura, J., Kubota, K., Murakami, H., Sawamura, M., Matsushima, T., Tamura, T., et al. Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin. Exp. Immunol. 116 (1999), 28–32.
77. [77] Grosse, L., Hoogenboezem, T., Ambree, O., Bellingrath, S., Jorgens, S., de Wit, H.J., et al. Deficiencies of the T and natural killer cell system in major depressive disorder: T regulatory cell defects are associated with inflammatory monocyte activation. Brain Behav. Immun. 54 (2016), 38–44.
78. [78] Park, E.J., Lee, J.H., Jeong, D.C., Han, S.I., Jeon, Y.W., Natural killer cell activity in patients with major depressive disorder treated with escitalopram. Int. Immunopharmacol. 28 (2015), 409–413.
79. [79] Patel, O., Kjer-Nielsen, L., Le Nours, J., Eckle, S.B., Birkinshaw, R., Beddoe, T., et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat. Commun., 4, 2013, 2142.
80. [80] Cowley, S.C., MAIT cells and pathogen defense. Cell. Mol. Life Sci. 71 (2014), 4831–4840.
81. [81] Suzuki, H., Kunisawa, J., Vitamin-mediated immune regulation in the development of inflammatory diseases. Endocr. Metab. Immune Disord. Drug Targets 15 (2015), 212–215.
82. [82] Maes, M., Stevens, W.J., DeClerck, L.S., Bridts, C.H., Peeters, D., Schotte, C., et al. A significantly increased number and percentage of B cells in depressed subjects: results of flow cytometric measurements. J. Affect. Disord. 24 (1992), 127–134.
83. [83] Onah, D.N., Hopkins, J., Luckins, A.G., Increase in CD5+ B cells and depression of immune responses in sheep infected with Trypanosoma evansi. Vet. Immunol. Immunopathol. 63 (1998), 209–222.
84. [84] Liu, W., Xue, J., Yu, S., Chen, Q., Li, X., Yu, R., Primary central nervous system lymphoma mimicking recurrent depressive disorder: a case report. Oncol. Lett. 9 (2015), 1819–1821.
85. [85] Wen, J., Doerner, J., Chalmers, S., Stock, A., Wang, H., Gullinello, M., et al. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. J. Neuroinflammation, 13, 2016, 73.
86. [86] Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006), 24–31.
87. [87] Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
88. [88] Singhal, G., Jaehne, E.J., Corrigan, F., Toben, C., Baune, B.T., Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci., 8, 2014, 315.
89. [89] Mossner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.C., Muller, N., et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J. Biol. Psychiatry 8 (2007), 141–174.
90. [90] Anforth, H.R., Bluthe, R.M., Bristow, A., Hopkins, S., Lenczowski, M.J., Luheshi, G., et al. Biological activity and brain actions of recombinant rat interleukin-1alpha and interleukin-1beta. Eur. Cytokine Netw. 9 (1998), 279–288.
91. [91] Black, C., Miller, B.J., Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry 78 (2014), 28–37.
92. [92] Politis, A., Olgiati, P., Malitas, P., Albani, D., Signorini, A., Polito, L., et al. Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. J. Alzheimers Dis. 19 (2010), 481–488.
93. [93] Baune, B.T., Smith, E., Reppermund, S., Air, T., Samaras, K., Lux, O., et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 37 (2012), 1521–1530.
94. [94] Vogelzangs, N., de Jonge, P., Smit, J.H., Bahn, S., Penninx, B.W., Cytokine production capacity in depression and anxiety. Transl. Psychiatry, 6, 2016, e825.
95. [95] Black, C., Miller, B.J., Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry 78 (2015), 28–37.
96. [96] Jonefjall, B., Ohman, L., Simren, M., Strid, H., IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm. Bowel Dis. 22 (2016), 2630–2640.
97. [97] Zhen, Y., Chu, C., Zhou, S., Qi, M., Shu, R., Imbalance of tumor necrosis factor-alpha, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Mol. Med. Rep. 47 (2015), 193–200.
98. [98] Steinman, L., Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat. Immunol. 11 (2010), 41–44.
99. [99] Beurel, E., Harrington, L.E., Jope, R.S., Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol. Psychiatry 73 (2013), 622–630.
100. [100] Liu, Y., Ho, R.C., Mak, A., The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int. J. Rheum. Dis. 15 (2012), 183–187.
101. [101] Kaster, M.P., Gadotti, V.M., Calixto, J.B., Santos, A.R., Rodrigues, A.L., Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 62 (2012), 419–426.
102. [102] Uguz, F., Kucuk, A., Aydogan, S., Arslan, S., Kurt, H.G., Toker, A., et al. Is major depression associated with serum levels of tumor necrosis factor-alpha in patients with rheumatoid arthritis?. J. Psychosom. Res. 79 (2015), 530–532.
103. [103] Horst, S., Chao, A., Rosen, M., Nohl, A., Duley, C., Wagnon, J.H., et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig. Dis. Sci. 60 (2015), 465–470.
104. [104] Guloksuz, S., Wichers, M., Kenis, G., Russel, M.G., Wauters, A., Verkerk, R., et al. Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability. PLoS One, 8, 2013, e60435.
105. [105] Sherman, M., Tsynman, D.N., Kim, A., Arora, J., Pietras, T., Messing, S., et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J. Dig. Dis. 15 (2014), 174–179.
106. [106] Uguz, F., Akman, C., Kucuksarac, S., Tufekci, O., Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin. Neurosci. 63 (2009), 50–55.
107. [107] Weinberger, J.F., Raison, C.L., Rye, D.B., Montague, A.R., Woolwine, B.J., Felger, J.C., et al. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav. Immun., 2014.
108. [108] Elgarf, A.S., Aboul-Fotouh, S., Abd-Alkhalek, H.A., El Tabbal, M., Hassan, A.N., Kassim, S.K., et al. Lipopolysaccharide repeated challenge followed by chronic mild stress protocol introduces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol. Biochem. Behav. 126 (2014), 152–162.
109. [109] Mendlovic, S., Mozes, E., Eilat, E., Doron, A., Lereya, J., Zakuth, V., et al. Immune activation in non-treated suicidal major depression. Immunol. Lett. 67 (1999), 105–108.
110. [110] Murakami, Y., Ishibashi, T., Tomita, E., Imamura, Y., Tashiro, T., Watcharanurak, K., et al. Depressive symptoms as a side effect of Interferon-alpha therapy induced by induction of indoleamine 2,3-dioxygenase 1. Sci. Rep., 6, 2016, 29920.
111. [111] Pokryszko-Dragan, A., Frydecka, I., Kosmaczewska, A., Ciszak, L., Bilinska, M., Gruszka, E., et al. Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin. Neurol. Neurosurg. 114 (2012), 1153–1158.
112. [112] Gananca, L., Oquendo, M.A., Tyrka, A.R., Cisneros-Trujillo, S., Mann, J.J., Sublette, M.E., The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology 63 (2016), 296–310.
113. [113] Buras, A., Waszkiewicz, N., Szulc, A., Depression and inflammation in rheumatic diseases. Postepy Hig. Med. Dosw. 70 (2016), 162–168.
114. [114] Schmidt, F.M., Schroder, T., Kirkby, K.C., Sander, C., Suslow, T., Holdt, L.M., et al. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 239 (2016), 85–91.
115. [115] Han, A., Yeo, H., Park, M.J., Kim, S.H., Choi, H.J., Hong, C.W., et al. IL-4/10 prevents stress vulnerability following imipramine discontinuation. J. Neuroinflammation, 12, 2015, 197.
116. [116] Roque, S., Correia-Neves, M., Mesquita, A.R., Palha, J.A., Sousa, N., Interleukin-10: a key cytokine in depression?. Cardiovasc. Psychiatry Neurol., 2009, 2009, 187894.
117. [117] Cao, G., Yang, Q., Zhang, S., Xu, C., Roberts, A.I., Wang, Y., et al. Mesenchymal stem cells prevent restraint stress-induced lymphocyte depletion via interleukin-4. Brain Behav. Immun. 38 (2014), 125–132.
118. [118] Voorhees, J.L., Tarr, A.J., Wohleb, E.S., Godbout, J.P., Mo, X., Sheridan, J.F., et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One, 8, 2013, e58488.
119. [119] Lee, K.M., Kim, Y.K., The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 6 (2006), 1298–1304.
120. [120] Scalabrino, G., Vitamin-regulated cytokines and growth factors in the CNS and elsewhere. J. Neurochem. 111 (2009), 1309–1326.
121. [121] Spinas, E., Saggini, A., Kritas, S.K., Cerulli, G., Caraffa, A., Antinolfi, P., et al. Crosstalk between vitamin B and immunity. J. Biol. Regul. Homeost. Agents 29 (2015), 283–288.
122. [122] Ji, Z., Fan, Z., Zhang, Y., Yu, R., Yang, H., Zhou, C., et al. Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. J. Immunol. 193 (2014), 2157–2167.
123. [123] Kjer-Nielsen, L., Patel, O., Corbett, A.J., Le Nours, J., Meehan, B., Liu, L., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491 (2012), 717–723.
124. [124] Digby, J.E., Martinez, F., Jefferson, A., Ruparelia, N., Chai, J., Wamil, M., et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 669–676.
125. [125] Chai, J.T., Digby, J.E., Ruparelia, N., Jefferson, A., Handa, A., Choudhury, R.P., Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One, 8, 2013, e62934.
126. [126] Lipszyc, P.S., Cremaschi, G.A., Zorrilla-Zubilete, M., Bertolino, M.L., Capani, F., Genaro, A.M., et al. Niacin modulates pro-inflammatory cytokine secretion: a potential mechanism involved in its anti-atherosclerotic effect. Open Cardiovasc. Med. J. 7 (2013), 90–98.
127. [127] Yanaka, N., Koyama, T.A., Komatsu, S., Nakamura, E., Kanda, M., Kato, N., Vitamin B6 suppresses NF-kappaB activation in LPS-stimulated mouse macrophages. Int. J. Mol. Med. 16 (2005), 1071–1075.
128. [128] Seemungal, T.A., Lun, J.C., Davis, G., Neblett, C., Chinyepi, N., Dookhan, C., et al. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. Int. J. Chron. Obstruct. Pulmon. Dis. 2 (2007), 313–321.
129. [129] Fu, L., Doreswamy, V., Prakash, R., The biochemical pathways of central nervous system neural degeneration in niacin deficiency. Neural Regen. Res. 9 (2014), 1509–1513.
130. [130] Meydani, S.N., Ribaya-Mercado, J.D., Russell, R.M., Sahyoun, N., Morrow, F.D., Gershoff, S.N., Vitamin B-6 deficiency impairs interleukin 2 production and lymphocyte proliferation in elderly adults. Am. J. Clin. Nutr. 53 (1991), 1275–1280.
131. [131] Murakami, K., Mizoue, T., Sasaki, S., Ohta, M., Sato, M., Matsushita, Y., et al. Dietary intake of folate, other B vitamins, and omega-3 polyunsaturated fatty acids in relation to depressive symptoms in Japanese adults. Nutrition 24 (2008), 140–147.
132. [132] Almeida, O.P., Ford, A.H., Flicker, L., Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int. Psychogeriatr. 27 (2015), 727–737.
133. [133] Au-Yeung, K.K., Yip, J.C., Siow, Y.L., K, O., Folic acid inhibits homocysteine-induced superoxide anion production and nuclear factor kappa B activation in macrophages. Can. J. Physiol. Pharmacol. 84 (2006), 141–147.
134. [134] Gross, R.L., Reid, J.V., Newberne, P.M., Burgess, B., Marston, R., Hift, W., Depressed cell-mediated immunity in megaloblastic anemia due to folic acid deficiency. Am. J. Clin. Nutr. 28 (1975), 225–232.
135. [135] Buccellato, F.R., Miloso, M., Braga, M., Nicolini, G., Morabito, A., Pravettoni, G., et al. Myelinolytic lesions in spinal cord of cobalamin-deficient rats are TNF-alpha-mediated. FASEB J. 13 (1999), 297–304.
136. [136] Kuroishi, T., Endo, Y., Muramoto, K., Sugawara, S., Biotin deficiency up-regulates TNF-alpha production in murine macrophages. J. Leukoc. Biol. 83 (2008), 912–920.
137. [137] Scalabrino, G., Corsi, M.M., Veber, D., Buccellato, F.R., Pravettoni, G., Manfridi, A., et al. Cobalamin (vitamin B(12)) positively regulates interleukin-6 levels in rat cerebrospinal fluid. J. Neuroimmunol. 127 (2002), 37–43.
138. [138] Juengel, E., Thomas, A., Rutz, J., Makarevic, J., Tsaur, I., Nelson, K., et al. Amygdalin inhibits the growth of renal cell carcinoma cells in vitro. Int. J. Mol. Med. 37 (2016), 526–532.
139. [139] Makarevic, J., Tsaur, I., Juengel, E., Borgmann, H., Nelson, K., Thomas, C., et al. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro. Life Sci. 147 (2016), 137–142.
140. [140] Qian, L., Xie, B., Wang, Y., Qian, J., Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int. J. Clin. Exp. Pathol. 8 (2015), 5363–5370.
141. [141] Chen, Y., Ma, J., Wang, F., Hu, J., Cui, A., Wei, C., et al. Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol. Immunotoxicol. 35 (2013), 43–51.
142. [142] Lee, H.M., Moon, A., Amygdalin regulates apoptosis and adhesion in Hs578T triple-negative breast cancer cells. Biomol. Ther. 24 (2016), 62–66.
143. [143] Sauer, H., Wollny, C., Oster, I., Tutdibi, E., Gortner, L., Gottschling, S., et al. Severe cyanide poisoning from an alternative medicine treatment with amygdalin and apricot kernels in a 4-year-old child. Wien. Med. Wochenschr. 165 (2015), 185–188.
144. [144] Blaheta, R.A., Nelson, K., Haferkamp, A., Juengel, E., Amygdalin, quackery or cure?. Phytomedicine 23 (2016), 367–376.
145. [145] Jiagang, D., Li, C., Wang, H., Hao, E., Du, Z., Bao, C., et al. Amygdalin mediates relieved atherosclerosis in apolipoprotein E deficient mice through the induction of regulatory T cells. Biochem. Biophys. Res. Commun. 411 (2011), 523–529.
146. [146] Yun, J.M., Im, S.B., Roh, M.K., Park, S.H., Kwon, H.A., Lee, J.Y., et al. Prunus yedoensis bark inhibits lipopolysaccharide-induced inflammatory cytokine synthesis by IkappaBalpha degradation and MAPK activation in macrophages. J. Med. Food 17 (2014), 407–413.